Clinuvel Pharmaceuticals Limited (CUV.AX)
AUD 10.76
(0.19%)
AUD 10.76
(0.19%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 78.09 Million AUD | 59.02% |
| 2023 | 50.58 Million AUD | 8.52% |
| 2022 | 46.61 Million AUD | 32.42% |
| 2021 | 35.2 Million AUD | 91.01% |
| 2020 | 18.43 Million AUD | -39.77% |
| 2019 | 30.6 Million AUD | 24.72% |
| 2018 | 24.53 Million AUD | 51.92% |
| 2017 | 16.15 Million AUD | 230.69% |
| 2016 | 4.88 Million AUD | 288.53% |
| 2015 | -2.59 Million AUD | -213.08% |
| 2014 | 2.29 Million AUD | 65.23% |
| 2013 | 1.38 Million AUD | 91.83% |
| 2012 | 722.8 Thousand AUD | -30.57% |
| 2011 | 1.04 Million AUD | 0.0% |
| 2010 | - AUD | 100.0% |
| 2009 | -916.53 Thousand AUD | 3.06% |
| 2008 | -945.44 Thousand AUD | -40.3% |
| 2007 | -673.85 Thousand AUD | -189.27% |
| 2006 | 754.84 Thousand AUD | 505.71% |
| 2005 | 124.62 Thousand AUD | 0.0% |
| 2004 | - AUD | 0.0% |
| 2003 | - AUD | 0.0% |
| 2002 | - AUD | 0.0% |
| 2001 | - AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 FY | 78.09 Million AUD | 54.37% |
| 2024 Q2 | 16.92 Million AUD | 0.0% |
| 2024 Q4 | 50.08 Million AUD | 0.0% |
| 2023 Q4 | 33.49 Million AUD | 0.0% |
| 2023 FY | 50.58 Million AUD | 8.52% |
| 2023 Q2 | 20.92 Million AUD | 0.0% |
| 2022 FY | 46.61 Million AUD | 32.42% |
| 2022 Q2 | 15.05 Million AUD | 0.0% |
| 2022 Q4 | 31.56 Million AUD | 0.0% |
| 2021 FY | 35.2 Million AUD | 91.01% |
| 2021 Q2 | 13.95 Million AUD | 0.0% |
| 2021 Q4 | 29.84 Million AUD | 0.0% |
| 2020 Q4 | 15.44 Million AUD | 0.0% |
| 2020 Q2 | 9.82 Million AUD | 0.0% |
| 2020 FY | 18.43 Million AUD | -39.77% |
| 2019 Q2 | 8.81 Million AUD | 0.0% |
| 2019 Q4 | 21.78 Million AUD | 0.0% |
| 2019 FY | 30.6 Million AUD | 24.72% |
| 2018 FY | 24.53 Million AUD | 51.92% |
| 2018 Q4 | 17.68 Million AUD | 0.0% |
| 2018 Q2 | 6.85 Million AUD | 0.0% |
| 2017 Q2 | 6.78 Million AUD | 0.0% |
| 2017 FY | 16.15 Million AUD | 230.69% |
| 2017 Q4 | 9.36 Million AUD | 0.0% |
| 2016 Q4 | 3.36 Million AUD | 0.0% |
| 2016 FY | 4.88 Million AUD | 288.53% |
| 2016 Q2 | 1.51 Million AUD | 0.0% |
| 2015 FY | -2.59 Million AUD | -213.08% |
| 2015 Q4 | -3.52 Million AUD | 0.0% |
| 2015 Q2 | 933.79 Thousand AUD | 0.0% |
| 2014 Q2 | 769.97 Thousand AUD | 0.0% |
| 2014 Q4 | 1.52 Million AUD | 0.0% |
| 2014 FY | 2.29 Million AUD | 65.23% |
| 2013 Q3 | 388.24 Thousand AUD | -57.66% |
| 2013 Q4 | 1.4 Million AUD | 262.27% |
| 2013 FY | 1.38 Million AUD | 91.83% |
| 2013 Q1 | 180.7 Thousand AUD | 0.0% |
| 2013 Q2 | 917.07 Thousand AUD | 407.51% |
| 2012 Q2 | 180.7 Thousand AUD | -30.57% |
| 2012 FY | 722.8 Thousand AUD | -30.57% |
| 2012 Q4 | 180.7 Thousand AUD | 0.0% |
| 2012 Q3 | 180.7 Thousand AUD | 0.0% |
| 2012 Q1 | 260.25 Thousand AUD | 0.0% |
| 2011 Q1 | - AUD | 0.0% |
| 2011 Q2 | 260.25 Thousand AUD | 0.0% |
| 2011 FY | 1.04 Million AUD | 0.0% |
| 2011 Q3 | 260.25 Thousand AUD | 0.0% |
| 2011 Q4 | 260.25 Thousand AUD | 0.0% |
| 2010 Q2 | - AUD | 100.0% |
| 2010 Q4 | - AUD | 0.0% |
| 2010 FY | - AUD | 100.0% |
| 2010 Q1 | -229.13 Thousand AUD | -0.0% |
| 2010 Q3 | - AUD | 0.0% |
| 2009 Q1 | -236.36 Thousand AUD | -0.0% |
| 2009 Q3 | -229.13 Thousand AUD | -0.0% |
| 2009 Q2 | -229.13 Thousand AUD | 3.06% |
| 2009 Q4 | -229.13 Thousand AUD | 0.0% |
| 2009 FY | -916.53 Thousand AUD | 3.06% |
| 2008 Q2 | -236.36 Thousand AUD | -40.3% |
| 2008 Q1 | -168.46 Thousand AUD | -0.0% |
| 2008 FY | -945.44 Thousand AUD | -40.3% |
| 2008 Q4 | -236.36 Thousand AUD | 0.0% |
| 2008 Q3 | -236.36 Thousand AUD | -0.0% |
| 2007 Q3 | -168.46 Thousand AUD | -0.0% |
| 2007 Q2 | -168.46 Thousand AUD | -189.27% |
| 2007 FY | -673.85 Thousand AUD | -189.27% |
| 2007 Q1 | 188.71 Thousand AUD | 0.0% |
| 2007 Q4 | -168.46 Thousand AUD | 0.0% |
| 2006 FY | 754.84 Thousand AUD | 505.71% |
| 2006 Q3 | 188.71 Thousand AUD | 0.0% |
| 2006 Q1 | 31.15 Thousand AUD | 0.0% |
| 2006 Q4 | 188.71 Thousand AUD | 0.0% |
| 2006 Q2 | 188.71 Thousand AUD | 505.72% |
| 2005 Q2 | 31.15 Thousand AUD | 0.0% |
| 2005 Q4 | 31.15 Thousand AUD | 0.0% |
| 2005 Q3 | 31.15 Thousand AUD | 0.0% |
| 2005 Q1 | - AUD | 0.0% |
| 2005 FY | 124.62 Thousand AUD | 0.0% |
| 2004 Q3 | - AUD | 0.0% |
| 2004 Q4 | - AUD | 0.0% |
| 2004 FY | - AUD | 0.0% |
| 2004 Q1 | - AUD | 0.0% |
| 2004 Q2 | - AUD | 0.0% |
| 2003 Q1 | - AUD | 0.0% |
| 2003 FY | - AUD | 0.0% |
| 2003 Q3 | - AUD | 0.0% |
| 2003 Q4 | - AUD | 0.0% |
| 2003 Q2 | - AUD | 0.0% |
| 2002 Q3 | - AUD | 0.0% |
| 2002 Q2 | - AUD | 0.0% |
| 2002 Q4 | - AUD | 0.0% |
| 2002 Q1 | - AUD | 0.0% |
| 2002 FY | - AUD | 0.0% |
| 2001 Q3 | - AUD | 0.0% |
| 2001 Q2 | - AUD | 0.0% |
| 2001 Q1 | - AUD | 0.0% |
| 2001 FY | - AUD | 0.0% |
| 2001 Q4 | - AUD | 0.0% |
| 2000 Q4 | - AUD | 0.0% |
| 2000 Q3 | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 2000 Q2 | - AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AdAlta Limited | 1.5 Million AUD | -5079.132% |
| Acrux Limited | -1.28 Million AUD | 6182.313% |
| Botanix Pharmaceuticals Limited | -6.55 Million AUD | 1292.039% |
| BTC Health Limited | 16.36 Thousand AUD | -477264.927% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | -947.755% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | -578.71% |
| Biome Australia Limited | 7.66 Million AUD | -918.258% |
| Hexima Limited | - AUD | -Infinity% |
| Immutep Limited | 1.44 Million AUD | -5308.732% |
| Memphasys Limited | 1606.00 AUD | -4862720.797% |
| Neuren Pharmaceuticals Limited | 205.17 Million AUD | 61.936% |
| Noxopharm Limited | -534.81 Thousand AUD | 14702.71% |
| Prescient Therapeutics Limited | 3.71 Million AUD | -2003.697% |
| Race Oncology Limited | 1.38 Million AUD | -5518.826% |
| Radiopharm Theranostics Limited | -21.3 Million AUD | 466.512% |
| Starpharma Holdings Limited | 7.65 Million AUD | -919.941% |
| Tissue Repair Ltd | 150.51 Thousand AUD | -51787.837% |
| Biotron Limited | -40.49 Thousand AUD | 192941.38% |
| Alterity Therapeutics Limited | 3.8 Million AUD | -1952.491% |
| CSL Limited | 15.28 Billion AUD | 99.489% |
| EZZ Life Science Holdings Limited | 50.94 Million AUD | -53.295% |
| Anatara Lifesciences Ltd | -748.91 Thousand AUD | 10528.076% |
| Bio-Gene Technology Limited | -301.44 Thousand AUD | 26007.169% |
| Zelira Therapeutics Limited | 10.28 Thousand AUD | -759302.003% |
| Patrys Limited | 1.39 Million AUD | -5501.705% |
| Orthocell Limited | 3.68 Million AUD | -2017.353% |
| Imugene Limited | -5.83 Million AUD | 1437.31% |
| PYC Therapeutics Limited | 22.05 Million AUD | -254.031% |
| Proteomics International Laboratories Limited | -1.12 Million AUD | 7053.14% |
| Cynata Therapeutics Limited | 2.31 Million AUD | -3272.58% |
| Arovella Therapeutics Limited | -25.97 Thousand AUD | 300715.505% |
| Nanollose Limited | -348.95 Thousand AUD | 22480.414% |
| Invex Therapeutics Ltd | 1.21 Million AUD | -6342.278% |
| NeuroScientific Biopharmaceuticals Limited | -91.33 Thousand AUD | 85604.124% |
| Amplia Therapeutics Limited | 4.01 Million AUD | -1847.189% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | -6139.89% |
| Nyrada Inc. | -5164.07 AUD | 1512413.001% |
| Telix Pharmaceuticals Limited | 308.5 Million AUD | 74.685% |
| Dimerix Limited | 583.47 Thousand AUD | -13284.721% |
| PharmAust Limited | -1641.00 AUD | 4759204.327% |
| AnteoTech Limited | 460.39 Thousand AUD | -16862.948% |
| Paradigm Biopharmaceuticals Limited | 56.81 Thousand AUD | -137365.504% |
| Recce Pharmaceuticals Ltd | -366.76 Thousand AUD | 21393.27% |
| Avecho Biotechnology Limited | -43.79 Thousand AUD | 178423.786% |
| Actinogen Medical Limited | 9.93 Million AUD | -686.355% |
| Immuron Limited | 3.33 Million AUD | -2240.475% |
| Argenica Therapeutics Limited | 2.59 Million AUD | -2906.112% |